Statins are recommended as the first-line therapy in most clinical guidelines due to their ability to lower C-reactive protein (CRP) levels, a key marker of arterial inflammation linked to heart attacks and strokes [7, 8] In Egypt, poor adherence to lipid-lowering therapy among patients with diabetes remains a significant challenge [9]. Here, CRP is linked to myocardial infarction.